BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS

Stock Information for Spruce Power Holding Corporation Class A

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Spruce Power Holding Corporation Class A

BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025
BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit
BrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting
BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq
BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update
BrainStorm Issues 2024 Letter to Shareholders
BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.